Search

Your search keyword '"Zelniker, Thomas A."' showing total 16 results

Search Constraints

Start Over You searched for: Author "Zelniker, Thomas A." Remove constraint Author: "Zelniker, Thomas A." Topic sodium-glucose transporter 2 inhibitors Remove constraint Topic: sodium-glucose transporter 2 inhibitors
16 results on '"Zelniker, Thomas A."'

Search Results

1. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.

2. SGLT2 inhibitors in heart failure: insights from plasma proteomics.

3. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

4. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.

5. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

6. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.

7. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

8. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.

10. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

11. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

12. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

13. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.

14. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

15. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

16. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.

Catalog

Books, media, physical & digital resources